201. Antiviral activity and synthesis of quaternized promazine derivatives against HSV-1
- Author
-
Ashley Roe, Shao-Chung Hsia, Akasha K. Purohit, Jacob J. Leichty, Lori M. Ward, Matthew Balish, and Miguel O. Mitchell
- Subjects
viruses ,Clinical Biochemistry ,Pharmaceutical Science ,Acyclovir ,HSL and HSV ,Herpesvirus 1, Human ,Virus Replication ,Biochemistry ,Antiviral Agents ,Green fluorescent protein ,Structure-Activity Relationship ,Phenothiazines ,Drug Discovery ,Chlorocebus aethiops ,medicine ,Structure–activity relationship ,Animals ,Humans ,Molecular Biology ,Vero Cells ,Treatment timing ,Promazine ,Chemistry ,Organic Chemistry ,Virology ,Quaternary Ammonium Compounds ,Viral replication ,Vero cell ,Molecular Medicine ,Antitubercular Agent ,medicine.drug - Abstract
N-(4-chlorobenzyl)triflupromazinium chloride, a known antitubercular agent, has been found to also be active against HSV-1. A preliminary structure-activity relation has been explored to determine which groups are crucial to viral inhibition. Antiviral assessments such as GFP reduction, plaque reduction, treatment timing and wash-out studies have also been probed to determine a mode of action for QPD-1. Based on this preliminary data, it appears that QPD-1 is a reversible inhibitor, suspected to inhibit early stages of viral replication of HSV-1 at 50 μM, equipotent to acyclovir.
- Published
- 2012